

## ***Alberta Drug Benefit List (ADBL) Interim Update now available online***

Please be advised that the **March 1, 2022** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

Please refer to the March 1, 2022 updates for complete listings of products available by special authorization, restricted benefit/special authorization, step therapy/special authorization, added products, new established interchangeable groupings, Least Cost Alternative (LCA) price changes, products with a price change, discontinued products and products removed from the *ADBL*.

Please note that the online Interactive Drug Benefit List (iDBL) at [ab.bluecross.ca/dbl/idbl\\_main1.php](http://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application and, as such, contains the most up-to-date information.

## **pan-Canadian Select Molecule Price Initiative for Generic Drugs**

### ***Alberta Drug Benefit List prices effective April 1, 2022***

The pan-Canadian Select Molecule Price Initiative, established in 2013 by the Health Care Innovation Working Group of the Council of the Federation, achieves better value for generic drugs by leveraging the combined purchasing power of participating jurisdictions to obtain the lowest generic prices achieved to date in Canada.

**Effective April 1, 2022, there will be no changes to the existing molecule list nor changes to existing price points.**

Through a pan-Canadian Price Confirmation process, manufacturers have confirmed their ability to supply the drugs included in this Initiative at the current price points to pharmacies in participating territories and provinces, including Alberta.

For more information on the pan-Canadian Select Molecule Price Initiative, including the existing molecule list and price points, please visit [pcpacanada.ca/generic-drug-framework](http://pcpacanada.ca/generic-drug-framework).

Please be advised that the April 1, 2022 Updates to the *ADBL* has been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

*continued next page*

continued from previous page

## Product supply shortage addressed for the Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Laboratoire Riva Inc. that the shortage for Riva-Pyridostigmine 60 mg Tablet (DIN 02495643) has been resolved. Due to the long-term nature of this shortage, a transition period will apply and, as a result, the LCA price policy will be reapplied to the following grouping effective **March 7, 2022**. The following grouping was removed from the Critical Supply Product List on **February 3, 2022**:

### PYRIDOSTIGMINE BROMIDE

#### 60 MG TABLET

00002495643	RIVA-PYRIDOSTIGMINE	RIV	\$ 0.4009
00000869961	MESTINON	VCL	\$ 0.4986

## Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Apo-Amitriptyline 75 mg Tablet (DIN 02403161) manufactured by Apotex Inc. and Elavil 75 mg Tablet (DIN 00754129) manufactured by AA Pharma Inc., Mar-Amitriptyline 75 mg Tablet (DIN 02429918) will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **February 1, 2022**.

As of **February 1, 2022**, all claims for Mar-Amitriptyline 75 mg Tablet (DIN 02429918) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php).

If this situation continues to be a long-term matter, this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)  
403-294-4041 (Calgary and area)  
1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area)  
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

